The facts
Latent Labs at a glance.
Read Oct 20, 2026. Valuations and amounts are copied as each source states them; a figure that is only reported (talks, or people familiar with the deal) is labeled as reported.
- Kind of company
- Drug discovery and biologyAI that designs drugs, proteins and antibodies.
- Based in
- London, United Kingdom
- Founded
- 2023TechCrunch, Paul Sawers, Feb 12, 2025
- Last closed-round valuation
- No valuation reported
- What it has shipped
- Has a model or API
Founders
- Simon Kohl: former DeepMind research scientist on the core AlphaFold2 team; co-led DeepMind's protein design team and set up its wet lab at the Francis Crick Institute (TechCrunch, Paul Sawers, Feb 12, 2025)
Opened Latent-Y to researchers worldwide; company reports "a 67% target-level success rate across nine targets" from its own work and a beta with three academic groups. Jul 15, 2026
Latent Labs press release (company), Jul 15, 2026
What it has built
Shipped, or not yet.
“Has a model or API” is what our search found: something the public can use or buy, a model or API, research only, or nothing public.
1 round
Funding, as reported.
Every round we found, with the amount, valuation and investors as the source states them.
| When | Round | Amount | Valuation | Investors named | Source |
|---|---|---|---|---|---|
| Feb 12, 2025 | Seed ($10M, previously unannounced) and Series A ($40M) | $50 million total | Not stated | Radical Ventures (Series A co-lead), Sofinnova Partners (Series A co-lead), Flying Fish, Isomer, 8VC, Kindred Capital, Pillar VC, Jeff Dean, Aidan Gomez, Mati Staniszewski | TechCrunch, Paul Sawers |
Our note
Worth knowing.
Our note: Incorporated in London in mid-2023 (TechCrunch); also has a San Francisco wet lab. No valuation found. Beta results at UC Davis, LMU University Hospital and TGen are reported by the company, not by those groups on pages fetched. No later funding found.
More drug discovery and biology